Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
REPL
REPL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REPL News
Replimune Reports Landmark Three-Year Survival Data
14h ago
NASDAQ.COM
Replimune Secures FDA Approval to Resubmit RP1 Application
20h ago
seekingalpha
Replimune Secures FDA Agreement, Shares Surge 80%
1d ago
stocktwits
Biotech Stocks Show Significant Pre-Market Activity
1d ago
NASDAQ.COM
Replimune Plans to Resubmit Melanoma Drug Application to FDA
1d ago
CNBC
Replimune Plans to Resubmit Melanoma Drug Application Following FDA Leadership Change
1d ago
Newsfilter
Replimune Plans to Resubmit RP1 Application After FDA Rejection
1d ago
seekingalpha
Replimune Aligns with FDA on RP1 Resubmission Pathway
1d ago
Newsfilter
Pomerantz LLP Investigates Replimune for Securities Fraud
May 21 2026
PRnewswire
Pomerantz LLP Investigates Replimune for Securities Fraud
May 19 2026
Globenewswire
Replimune Group Faces Securities Investigation
May 18 2026
Globenewswire
Pomerantz LLP Investigates Replimune for Securities Fraud
May 15 2026
PRnewswire
FDA Commissioner's Departure Triggers Biotech Market Reactions
May 13 2026
Newsfilter
Replimune Shares Surge 30% Following FDA Leadership Change
May 13 2026
seekingalpha
Pomerantz LLP Investigates Replimune for Securities Fraud
May 12 2026
Globenewswire
FDA Commissioner Resignation Triggers Stock Movements
May 12 2026
stocktwits
Show More News
